. Author manuscript; available in PMC: 2012 May 1.

Published in final edited form as: Am J Kidney Dis. 2011 Mar 10;57(5):724–732. doi: 10.1053/j.ajkd.2010.12.016

Table 3.

ICER of Adjuvanted versus Non-Adjuvanted Vaccine

Adjuvant Efficacy	Influenza Clinical Attack Rate
Adjuvant Efficacy	Base Case^‡	12.50%	15.00%	17.50%	20.00%
Adjuvant Cost=$1
20%	208,861	248,331	58,642	16,390	Dominated^*
40%	85,323	108,499	Dominated^*	Dominated^*	Dominated^*
60%	32,433	20,185	Dominated^*	Dominated^*	Dominated^*
80%	3,275	12,249	Dominated^*	Dominated^*	Dominated^*
100%^†	Dominated^*	Dominated^*	Dominated^*	Dominated^*	Dominated^*
Adjuvant Cost=$2
20%	525,475	419,332	153,765	51,397	Dominated^*
40%	193,703	122,258	33,166	1,061	Dominated^*
60%	99,801	70,803	Dominated^*	Dominated^*	Dominated^*
80%	53,634	37,536	Dominated^*	Dominated^*	Dominated^*
100%^†	38,357	16,851	Dominated^*	Dominated^*	Dominated^*
Adjuvant Cost=$5
20%	1,128,830	1,087,534	439,505	249,265	32,665
40%	525,173	458,354	154,171	93,731	Dominated^*
60%	227,850	361,572	102,060	37,879	Dominated^*
80%	241,426	226,823	49,969	13,647	Dominated^*
100%^†	192,097	185,804	26,340	Dominated^*	Dominated^*

Values are presented ICERs with units of $/QALY. Shaded values indicate cases where the adjuvanted strategy is cost-effective.

Adjuvanted vaccine strategy dominates the non-adjuvanted vaccine strategy (i.e. less costly and more effective)

^†

100% adjuvant efficacy denotes influenza vaccine efficacy equal to that of a healthy adult.

^‡

The base case clinical influenza attack rate draws from a triangular distribution, with mean: 0.125, range: 0.05-0.20.

ICER, Incremental Cost-Effectiveness Ratio